Welcome to QBiotics

An Australian naturally inspired life sciences company

Human Health
Animal Health
Investor Health

Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses

September 2019

Dr Chad Johannes DVM, Diplomate ACVIM (SAIM, Oncology) presented the tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results at two recent prestigious international congresses: European Society of Veterinary Oncology (ESVONC) and American College of Veterinary Internal Medicine Forum (ACVIM).

The clinical trial results of 75% Complete Response (full tumour destruction) with a single injection was enthusiastically received by the audiences at both conferences, which consisted of a mix of oncologists and general practitioner veterinarians.

Publications: